COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
14 hedge funds and large institutions have $3.76M invested in COSCIENS Biopharma Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 7 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
18% less funds holding
Funds holding: 17 → 14 (-3)
31% less capital invested
Capital invested by funds: $5.46M → $3.76M (-$1.71M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$95.6K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$72.2K |
| 3 |
Jane Street
New York
|
+$64.9K |
| 4 |
Millennium Management
New York
|
+$62.6K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$47.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$631K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$137K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$109K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$20K |
| 5 |
Walleye Trading
New York
|
-$8K |
CSCI Hedge Fund Activity: Q1 2016 in Review
14 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q1 2016, worth a combined $3.76M — down 31% from $5.46M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CSCI and 4 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $95.6K. The largest seller was Oxford Asset Management, exiting entirely with an estimated $631K sold.
- 14 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q1 2016, down from 17 in Q4 2015.
- Funds reported $3.76M of COSCIENS Biopharma Inc. Common Stock stock for Q1 2016, down 31% quarter-over-quarter.
- 4 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q1 2016 and 7 closed out, a net change of -3 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q1 2016 was Renaissance Technologies, an estimated $95.6K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q1 2016 was Oxford Asset Management, an estimated $631K sold.
Based on aggregated 13F filings for Q1 2016.